EyeGate Pharma (Wlatham, MA) a clinical-stage company focused on a non-invasive iontophoresis drug delivery system for ocular therapeutics, closed a $22.6M Series D financing. Participants include Natixis Private Equity, Emerging Capital, Ventech, Innoven Partners and Medicis Capital.